CEO Interview
BrainStorm Cell Therapeutics (NASDAQ: BCLI) Stem cell therapy for ALS in Phase III FDA trials
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) interview with CEO, Chaim Lebovits, discussing the company’s advancements in developing stem cell therapies to treat neurodegenerative diseases. The company’s pipeline includes a lead indication for ALS- Amyotrophic Lateral […]